Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum
Carregando...
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
MONTEIRO, Lis Marie
LOBENBERG, Raimar
BARBOSA, Eduardo Jose
ARAUJO, Gabriel Lima Barros de
FOTAKI, Nikoletta
Citação
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, v.169, article ID 106097, 11p, 2022
Resumo
Leishmaniasis, a neglected tropical disease, is prevalent in 98 countries with the occurrence of 1.3 million new cases annually. The conventional therapy for visceral leishmaniasis requires hospitalization due to the severe adverse effects of the drugs, which are administered parenterally. Buparvaquone (BPQ) showed in vitro activity against leishmania parasites; nevertheless, it has failed in vivo tests due to its low aqueous solubility. Though, lipid nanoparticles can overcome this holdback. In this study we tested the hypothesis whether BPQ-NLC shows in vivo activity against L. infantum. Two optimized formulations were prepared (V1: 173.9 +/- 1.6 nm, 0.5 mg of BPQ/mL; V2: 232.4 +/- 1.6 nm, 1.3 mg of BPQ/mL), both showed increased solubility up to 73.00-fold, and dissolution up to 83.29%, while for the free drug it was only 2.89%. Cytotoxicity test showed their biocompatibility (CC50 >554.4 mu M). Besides, the V1 dose of 0.3 mg/kg/day for 10 days reduced the parasite burden in 83.4% +/- 18.2% (p <0.05) in the liver. BPQ-NLC showed similar leishmanicidal activity compared to miltefosine. Therefore, BPQ-NLC is a promising addition to the limited therapeutic arsenal suitable for leishmaniasis oral administration treatment.
Palavras-chave
Buparvaquone, Nanostructured lipid carrier, Leishmaniasis, Neglected diseases
Referências
- Adhikari U, 2016, J PHYS CHEM B, V120, P5823, DOI 10.1021/acs.jpcb.5b11448
- Alavi Mehran, 2019, Drug Metabolism and Personalized Therapy, V34, P20180032, DOI 10.1515/dmpt-2018-0032
- [Anonymous], 2017, Wkly Epidemiol Rec, V92, P557
- AURES II, 2020, POLYM DATABASE WWW D
- Beloqui A, 2016, NANOMED-NANOTECHNOL, V12, P143, DOI 10.1016/j.nano.2015.09.004
- Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2
- CROFT SL, 1992, J ANTIMICROB CHEMOTH, V30, P827, DOI 10.1093/jac/30.6.827
- da Costa-Silva TA, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02297-16, 10.1128/aac.02297-16]
- Das S, 2012, EUR J PHARM SCI, V47, P139, DOI 10.1016/j.ejps.2012.05.010
- Date AA, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/27/275102
- Date T, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-018-1272-0
- de Souza A, 2018, INT J PHARMACEUT, V547, P421, DOI 10.1016/j.ijpharm.2018.06.018
- Jimenez-Anton MD, 2019, METHODS MOL BIOL, V1971, P303, DOI 10.1007/978-1-4939-9210-2_17
- Dorlo TPC, 2008, ANTIMICROB AGENTS CH, V52, P2855, DOI 10.1128/AAC.00014-08
- Dorlo TPC, 2012, J ANTIMICROB CHEMOTH, V67, P2576, DOI 10.1093/jac/dks275
- Fortin A, 2012, J ANTIMICROB CHEMOTH, V67, P2707, DOI 10.1093/jac/dks273
- Gordillo-Galeano A, 2018, EUR J PHARM BIOPHARM, V133, P285, DOI 10.1016/j.ejpb.2018.10.017
- Hendrickx S, 2015, ANTIMICROB AGENTS CH, V59, P4714, DOI 10.1128/AAC.00707-15
- Jain A, 2004, AAPS PHARMSCITECH, V5, DOI 10.1208/pt050345
- Jogia H, 2014, DISSOLUT TECHNOL, V21, P45, DOI 10.14227/DT210114P45
- Kobets T, 2012, CURR MED CHEM, V19, P1443, DOI 10.2174/092986712799828300
- Korani S, 2019, DRUG DISCOV TODAY, V24, P567, DOI 10.1016/j.drudis.2018.09.023
- Lima SC, 2012, INT J ANTIMICROB AG, V39, P424, DOI 10.1016/j.ijantimicag.2012.01.003
- Lowe ME, 2015, GASTROENTEROLOGY, V149, P1678, DOI 10.1053/j.gastro.2015.10.025
- Meira CD, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7120695
- Melby PC, 2001, J IMMUNOL, V166, P1912, DOI 10.4049/jimmunol.166.3.1912
- Melo GD, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005924
- Michel G, 2011, ACTA TROP, V119, P69, DOI 10.1016/j.actatropica.2011.05.012
- Minekus M, 2014, FOOD FUNCT, V5, P1113, DOI 10.1039/c3fo60702j
- Monteiro LM, 2017, INT J ANTIMICROB AG, V50, P88, DOI 10.1016/j.ijantimicag.2017.01.033
- Monteiro LM, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9781603
- Murray HW, 2001, INT J EXP PATHOL, V82, P249, DOI 10.1046/j.1365-2613.2001.00199.x
- Park SJ, 2017, FOOD CHEM, V225, P213, DOI 10.1016/j.foodchem.2017.01.015
- Tran P, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11030132
- Reimao JQ, 2020, EXPERT OPIN DRUG DIS, V15, P647, DOI 10.1080/17460441.2020.1743674
- Reimao JQ, 2012, EXP PARASITOL, V130, P195, DOI 10.1016/j.exppara.2012.01.010
- Savic V, 2019, INT J PHARMACEUT, V569, DOI 10.1016/j.ijpharm.2019.118624
- Shrivastava S, 2021, PARTICUL SCI TECHNOL, V39, P380, DOI 10.1080/02726351.2020.1750515
- Smith L, 2018, MOL PHARMACEUT, V15, P2570, DOI 10.1021/acs.molpharmaceut.8b00097
- Souto EB, 2020, EXPERT OPIN DRUG DEL, V17, P357, DOI 10.1080/17425247.2020.1727883
- Stetefeld Jorg, 2016, Biophys Rev, V8, P409, DOI 10.1007/s12551-016-0218-6
- Sunyoto T, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000709
- Sznitowska M, 2017, EUR J PHARM BIOPHARM, V110, P24, DOI 10.1016/j.ejpb.2016.10.023
- Teeranachaideekul V, 2008, J CONTROL RELEASE, V128, P134, DOI 10.1016/j.jconrel.2008.02.011
- Thapa R, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009533
- Thomaidou E, 2015, AM J TROP MED HYG, V93, P770, DOI 10.4269/ajtmh.14-0787
- Torcello-Gomez A, 2014, CARBOHYD POLYM, V113, P53, DOI 10.1016/j.carbpol.2014.06.070
- Ustundag-Okur N, 2016, J MICROENCAPSUL, V33, P30, DOI 10.3109/02652048.2015.1094532
- Vexenat JA, 1998, VET PARASITOL, V77, P71, DOI 10.1016/S0304-4017(96)01150-8
- Vishwakarma N, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1293-3
- Witayaudom P, 2017, J COLLOID INTERF SCI, V505, P1082, DOI 10.1016/j.jcis.2017.07.008
- Wu GH, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.028101
- Zoubari G, 2017, EUR J PHARM BIOPHARM, V110, P39, DOI 10.1016/j.ejpb.2016.10.021